PDF(Pubmed)
Abstract：
Clear cell carcinoma is a rare and very aggressive subset of cervical cancer, with poor outcome if diagnosed at advanced stage. There are few data available on the optimal management of this histotype, and treatment recommendations that include surgery and chemoradiotherapy, are essentially based on those for squamous cell carcinoma. Here we report the case of a young patient newly diagnosed with advanced stage (FIGO IIB) clear cell carcinoma of the uterine cervix who received a window of opportunity one injection of nivolumab followed by standard chemoradiotherapy. She showed a persistent complete remission after 28 months of follow-up, but developed hypothyroidism, as a consequence of immunotherapy, and required lifelong thyroid hormone replacement.
摘要：
透明细胞癌是一种罕见且极具侵袭性的子宫颈癌，如果诊断为晚期，结果较差。关于这种组织型的最佳管理的数据很少，以及包括手术和放化疗在内的治疗建议，基本上是基于鳞状细胞癌。在这里，我们报告了一名新诊断为晚期（FIGOIIB）宫颈透明细胞癌的年轻患者的病例，该患者接受了一次机会窗口，一次注射nivolumab，然后进行标准放化疗。经过28个月的随访，她表现出持续的完全缓解，但是出现了甲状腺功能减退，作为免疫疗法的结果，需要终身更换甲状腺激素.
